Associations Between Quality of Life and Disease Progression in Metastatic Hormone-sensitive Prostate Cancer: Insights from ARASENS and ARANOTE Trials [0.03%]
PROSTATE ARASENS和ARANOTE研究中转移性激素敏感型前列腺癌患者生活质量与疾病进展的相关性分析
Alicia K Morgans,Sara Ekberg,Martin Boegemann et al.
Alicia K Morgans et al.
Background: Maintaining quality of life (QoL) is an important treatment goal in metastatic hormone-sensitive prostate cancer (mHSPC). Evidence remains limited regarding longitudinal QoL changes, prognostic value, and cont...
Reply to Shilpa Gupta, Maria Carmen Mir, and Daniel E. Spratt's Letter to the Editor re: Riccardo Bertolo, Antonio Luigi Pastore, Paolo Verze, et al. Real-world Burden and Management of Late Genitourinary Toxicity after Prostate Radiotherapy: Insights from IRRADIaTE, the Italian Registry of Radiotherapy-associated Disorders and Urological Treat [0.03%]
关于希尔帕·古普塔、玛丽亚·克梅恩·米尔斯以及丹尼尔·埃·斯普拉特致编辑的信函对里卡多·贝托洛、安东尼奥·卢伊吉·巴斯托雷、保罗·韦茨等作者题为“放射登记：意大利放射治疗相关疾病和泌尿系统治疗注册研究（IRRADIaTE）中前列腺放疗后晚期泌尿系统毒副反应的负担和处理”的回复
Riccardo Bertolo,Alessandro Veccia,Alessandro Antonelli
Riccardo Bertolo
Re: Bertolo R, Pastore AL, Verze P, et al. Real-world Burden and Management of Late Genitourinary Toxicity after Prostate Radiotherapy: Insights from IRRADIaTE, the Italian Registry of Radiotherapy-associated Disorders and Urological Treatment & Evaluation. Eur Urol Oncol. In press. http://dx.doi.org/10.1016/j.euo.2026.01.005 [0.03%]
关于Bertolo R, Pastore AL, Verze P等人的评论：前列腺放射治疗后晚期泌尿系统毒性的真实世界负担和管理：来自IRRADIaTE的见解，这是一个关于放射治疗相关障碍和泌尿外科治疗与评估的意大利注册数据库。Eur Urol Oncol. 在线发表。http://dx.doi.org/10.1016/j.euo.2026.01.005
Shilpa Gupta,Maria Carmen Mir,Daniel E Spratt
Shilpa Gupta
Immunotherapy Escalation in BCG-Naïve NMIBC: Time for Selectivity, Not Enthusiasm [0.03%]
BCG初治的NMIBC免疫治疗：此时需要选择性治疗，而不是盲目热情
Marco Moschini,Maria Carmen Mir,Jonathan Aning et al.
Marco Moschini et al.
Unveiling the Clinical Potential of Prostate Cancer Three-dimensional Models: A Systematic Review [0.03%]
前列腺癌三维模型的临床潜力：系统性综述
Arthur Peyrottes,Norbert de Brek,Anne-Sophie Vieira Aleixo et al.
Arthur Peyrottes et al.
Background: Patient-derived organoids (PDOs) and organotypic slice tissues have emerged as promising platforms to model prostate cancer (PCa) in three dimensions (3D), preserving tumor architecture and molecular features....
Reply to: Russi's Letter to the Editor re: Riccardo Bertolo, Antonio Luigi Pastore, Paolo Verze, et al. Real-World Burden and Management of Late Genitourinary Toxicity After Prostate Radiotherapy: Insights from IRRADIaTE, the Italian Registry of Radiotherapy-Associated Disorders and Urological Treatment & Evaluation. Eur Urol Oncol. In [0.03%]
关于Russi的信：Bertolo R，Pastore AL，Verze P等。放射治疗后的前列腺晚期泌尿系统毒性在真实世界中的负担和管理：来自意大利放射治疗相关障碍和泌尿外科治疗与评估登记处（IRRADIaTE）的见解《欧洲泌尿肿瘤学》杂志，在线发表
Riccardo Bertolo,Alessandro Antonelli
Riccardo Bertolo
Agentic AI for Prostate Cancer: A Vision for Multimodal Clinical Intelligence [0.03%]
前列腺癌的代理式人工智能：多模态临床智能的愿景
N Papanikolaou,A R Padhani,F Sanguedolce
N Papanikolaou
While artificial intelligence (AI) is rapidly advancing in prostate cancer diagnostics and therapy planning, its impact on everyday clinical decision-making remains marginal. To fill this gap, "Agentic AI systems" are under development: wor...
Pragmatic Clinical End points for High-risk NMIBC: A Path to Accelerated Market Access in Europe [0.03%]
高危NMIBC临床实用终点：欧洲市场加速准入之路
Evanguelos Xylinas,Félix Guerrero-Ramos,Shahrokh F Shariat et al.
Evanguelos Xylinas et al.
Re: Blackmur JP, Rossi SH, Kuusk T, et al. Prediction Models for Shared Decision-making by Patients with Localised Renal Masses: A Systematic Review and a Survey of Patient and Clinician Priorities. Eur Urol Oncol. In press. http://dx.doi.org/10.1016/j.euo.2026.02.008: Outcome Prediction in Localised Renal Cancer: We Need to Do Better [0.03%]
关于Blackmur JP, Rossi SH, Kuusk T等人。预测模型在局部肾肿物患者的共同决策中：系统综述和患者及临床医生优先事项调查。 Eur Urol Oncol. 在线发表。 http://dx.doi.org/10.1016/j.euo.2026.02.008：局灶性肾癌的预后预测：我们需要做得更好
Eduard Roussel,Daniele Amparore,Maarten Albersen
Eduard Roussel
Methodological Considerations on Causal Interpretability of the IRRADIaTE Registry [0.03%]
Irradiate登记处因果可解释性的方法学考量
Alessio Bruni,Giacomo Ferrantelli,Elvio G Russi
Alessio Bruni